Core Viewpoint - Recently, Baicheng Pharmaceutical announced a collaboration with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the exclusive authorization of the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1: Collaboration Details - The collaboration involves a technical development cooperation agreement and a supplementary agreement, which will take effect after approval by the company's shareholders' meeting [1] - The agreement is classified as a related party transaction due to the involvement of Feng Enguang, the legal representative and senior management of Zhongshen Innovation, who previously served as the deputy general manager of Baicheng Pharmaceutical [1] Group 2: Regulatory Compliance - The transaction is in accordance with the Shenzhen Stock Exchange's Growth Enterprise Market Listing Rules, which define individuals who have served as senior management within the past twelve months as related natural persons [1]
百诚医药：与浙江众神创新就BIOS-0629项目签署《技术开发合作协议》